Mission Statement

Celtic Pharma’s mission is to be the premier global private equity firm focused on pharmaceuticals and biological drugs.

Celtic seeks to:

  • Acquire ownership or controlling stakes in differentiated and commercially attractive pharmaceutical products in the late stages of clinical and regulatory development;
  • Build real value with these assets by driving them through the final stages of the drug approval process, employing its in-house “virtual pharma” model of drug development infrastructure; and
  • Achieve extraordinary returns for its investors by monetizing these important and innovative drugs as launch-ready assets through transactions with major pharmaceutical companies, the larger biotechnology companies and/or the capital markets.

Recent Highlights

12.04.07: Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on XERECEPT® Clinical Program
Read the full press release
10.29.07: Celtic Pharma completes rapid enrollment in Phase IIB study for TA-NIC, the nicotine vaccine for smoking cessation
Read the full press release
10.15.07: Celtic Pharma Announces Initiation of Phase II Clinical Trial for TDT-067, a Treatment for Onychomycosis
Read the full press release
09.06.07: Celtic Pharma portfolio company, IDEA AG, signs major licensing agreement with Alpharma Inc.
Read the full press release
06.05.07: Celtic Pharma and Neurobiological Technologies report Updated results from Long-term open-label extension study for Xerecept, and its clinical development status.
Read the full press release
04.30.07: Celtic Pharma receives IND approval to initiate a large randomized study in the US for TA-NIC, its immunotherapy vaccine for the treatment of smoking cessation.
Read the full press release
02.07.07: Celtic Pharma raises $156 million in debt bringing total capital to over $400 million.
Read the full press release
02.07.07: Celtic Pharma announces the termination of trial KSB311R/CIII/001 of its investigational new drug TransMID™
Read the full press release